{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:33:06Z","timestamp":1775136786800,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>An increase of IGF-1 has been reported during therapy with dopamine agonists (DA) for prolactinomas; in such cases a correct diagnosis is pivotal to avoid an unnecessary reduction or withdrawal of DA, which are needed to maintain normal prolactin levels. This study was aimed to measure IGF-1 levels, at baseline and during follow-up, in a cohort of patients with prolactinoma, treated with cabergoline, stratified by body mass index.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively enrolled 35 patients (15 F\/20\u00a0M; age m\u2009\u00b1\u2009SD, years: 43.4\u2009\u00b1\u200913.7) with prolactinoma (21 microadenomas and 14 macroadenomas) who were followed-up at the Endocrinology Unit, in Siena, and with available pituitary hormone assessment at baseline and during follow-up (m\u2009\u00b1\u2009SD, years: 2.74\u2009\u00b1\u20090.55).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>IGF-1 increased in the whole cohort, but remaining within normal range, except two patients, in whom acromegaly was ruled out with oral glucose tolerance test. After dividing patients by weight, this trend was confirmed only in subjects with overweight and obesity (OV\/OB) (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). Interestingly, the reduction of prolactin levels was significantly greater in the OV\/OB compared to normal-weight patients (median decrease of 97.5% versus 88.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Since DA and normalization of prolactin are known to improve insulin sensitivity, we speculated they have favored the increase of IGF-1 in OV\/OB. Our results should be confirmed and the hypothesis proven by further studies.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-024-01622-4","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:03:20Z","timestamp":1718877800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight"],"prefix":"10.1186","volume":"24","author":[{"given":"S.","family":"Caprio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1171-6384","authenticated-orcid":false,"given":"T.","family":"Pilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-295X","authenticated-orcid":false,"given":"S.","family":"Cantara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sestini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ciuoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dalmiglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-1751","authenticated-orcid":false,"given":"M. G.","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","unstructured":"Manuylova E, Calvi LM, Hastings C, Vates GE, Johnson MD, Cave WT Jr, Shafiq I. Late presentation of acromegaly in medically controlled prolactinoma patients. Endocrinol Diabetes Metab Case Rep. 2016. https:\/\/doi.org\/10.1530\/EDM-16-0069.","DOI":"10.1530\/EDM-16-0069"},{"key":"1622_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01338-x","author":"C Bona","year":"2021","unstructured":"Bona C, Prencipe N, Jaffrain-Rea ML, Carosi G, Lanzi R, Ambrosio MR, Pasquali D, Vettor R, Cannav\u00f2 S, Ghigo E, Grottoli S. The prevalence of silent acromegaly in prolactinomas is very low. J Endocrinol Invest. 2021. https:\/\/doi.org\/10.1007\/s40618-020-01338-x.","journal-title":"J Endocrinol Invest"},{"key":"1622_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0891-5","author":"A Akirov","year":"2018","unstructured":"Akirov A, Greenman Y, Glaser B, S\u2019chigol I, Mansiterski Y, Eizenberg Y, Shraga-Slutzky I, Shimon I. IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Pituitary. 2018. https:\/\/doi.org\/10.1007\/s11102-018-0891-5.","journal-title":"Pituitary"},{"key":"1622_CR4","doi-asserted-by":"publisher","unstructured":"Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022. https:\/\/doi.org\/10.3389\/fendo.2022.1015520.","DOI":"10.3389\/fendo.2022.1015520"},{"key":"1622_CR5","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1833","author":"N Friedrich","year":"2012","unstructured":"Friedrich N, Thuesen B, J\u00f8rgensen T, Juul A, Spielhagen C, Wallaschofksi H, Linneberg A. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012. https:\/\/doi.org\/10.2337\/dc11-1833.","journal-title":"Diabetes Care"},{"key":"1622_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02557-1","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Christ E. Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine. 2021. https:\/\/doi.org\/10.1007\/s12020-020-02557-1.","journal-title":"Endocrine"},{"key":"1622_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800412","author":"SY Nam","year":"1997","unstructured":"Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 1997. https:\/\/doi.org\/10.1038\/sj.ijo.0800412.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1622_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2019.104551","author":"H Wei","year":"2020","unstructured":"Wei H, Zapata RC, Lopez-Valencia M, Aslanoglou D, Farino ZJ, Benner V, Osborn O, Freyberg Z, McCarthy MJ. Dopamine D2 receptor signaling modulates pancreatic beta cell circadian rhythms. Psychoneuroendocrinology. 2020. https:\/\/doi.org\/10.1016\/j.psyneuen.2019.104551.","journal-title":"Psychoneuroendocrinology"},{"key":"1622_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-015-0094-4","author":"NA Pala","year":"2015","unstructured":"Pala NA, Laway BA, Misgar RA, Dar RA. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015. https:\/\/doi.org\/10.1186\/s13098-015-0094-4.","journal-title":"Diabetol Metab Syndr"},{"key":"1622_CR10","doi-asserted-by":"publisher","unstructured":"Cozzi R, Ambrosio MR, Attanasio R, Battista C, Bozzao A, Caputo M, Ciccarelli E, De Marinis L, De Menis E, Faustini Fustini M, Grimaldi F, Lania A, Lasio G, Logoluso F, Losa M, Maffei P, Milani D, Poggi M, Zini M, Katznelson L, Luger A, Poiana C. Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol. 2022. https:\/\/doi.org\/10.1530\/EJE-21-0977.","DOI":"10.1530\/EJE-21-0977"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01622-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:06:38Z","timestamp":1718877998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01622-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01622-4","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committee of the University Hospital of Siena and patients gave a written informed consent before participating.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}